Research Analysts Set Expectations for SGMT Q4 Earnings

Sagimet Biosciences Inc. (NASDAQ:SGMT) – HC Wainwright dropped their Q4 2026 earnings per share (EPS) estimates for Sagimet Biosciences in a note issued to investors on Tuesday, August 11th. HC Wainwright analyst B. Folkes now forecasts that the company will post earnings per share of ($0.32) for the quarter, down from their previous forecast of ($0.30). The consensus estimate for Sagimet Biosciences’ current full-year earnings is ($1.15) per share.

A number of other equities analysts have also issued reports on the stock. Canaccord Genuity Group boosted their target price on shares of Sagimet Biosciences from $49.00 to $56.00 and gave the stock a “buy” rating in a research report on Wednesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Sagimet Biosciences in a report on Friday, July 17th. Guggenheim decreased their price target on shares of Sagimet Biosciences from $27.00 to $25.00 and set a “buy” rating on the stock in a research report on Wednesday, April 29th. Oppenheimer restated an “outperform” rating on shares of Sagimet Biosciences in a report on Friday, May 1st. Finally, Citizens Jmp cut their price objective on shares of Sagimet Biosciences from $35.00 to $12.00 and set a “market outperform” rating for the company in a research report on Tuesday, May 19th. Seven analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Sagimet Biosciences has a consensus rating of “Moderate Buy” and a consensus price target of $26.33.

Sagimet Biosciences Stock Performance

Sagimet Biosciences stock opened at $9.39 on Thursday. The business’s 50-day simple moving average is $7.39 and its 200-day simple moving average is $6.52. The firm has a market capitalization of $305.93 million, a PE ratio of -7.34 and a beta of 3.37. Sagimet Biosciences has a 52 week low of $4.50 and a 52 week high of $10.06.

Sagimet Biosciences (NASDAQ:SGMT) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.01).

Insider Activity at Sagimet Biosciences

In related news, insider Elizabeth Rozek sold 10,545 shares of the firm’s stock in a transaction on Monday, July 20th. The stock was sold at an average price of $7.76, for a total value of $81,829.20. Following the completion of the transaction, the insider directly owned 224,414 shares of the company’s stock, valued at $1,741,452.64. This trade represents a 4.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director George Kemble sold 20,206 shares of Sagimet Biosciences stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $9.95, for a total transaction of $201,049.70. Following the sale, the director owned 62,161 shares in the company, valued at $618,501.95. This represents a 24.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 113,646 shares of company stock worth $920,491. 11.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Sagimet Biosciences

Several hedge funds and other institutional investors have recently modified their holdings of SGMT. Renaissance Technologies LLC boosted its stake in Sagimet Biosciences by 82.6% in the 1st quarter. Renaissance Technologies LLC now owns 625,469 shares of the company’s stock valued at $3,268,000 after buying an additional 282,969 shares in the last quarter. Dimensional Fund Advisors LP grew its position in Sagimet Biosciences by 99.4% in the first quarter. Dimensional Fund Advisors LP now owns 271,217 shares of the company’s stock valued at $1,415,000 after acquiring an additional 135,178 shares during the period. Dumac Inc. acquired a new position in Sagimet Biosciences during the fourth quarter worth $421,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Sagimet Biosciences during the fourth quarter valued at $30,000. Finally, Royal Bank of Canada boosted its stake in shares of Sagimet Biosciences by 819.2% in the 4th quarter. Royal Bank of Canada now owns 4,927 shares of the company’s stock valued at $29,000 after purchasing an additional 4,391 shares in the last quarter. Institutional investors own 87.86% of the company’s stock.

Key Headlines Impacting Sagimet Biosciences

Here are the key news stories impacting Sagimet Biosciences this week:

• Positive Sentiment: Canaccord raises price target: Canaccord Genuity lifted its target for Sagimet from $49 to $56 and maintained a “buy” rating, implying substantial potential upside from recent trading levels. The upgrade reflects a bullish view of the company’s development prospects. Benzinga analyst price target report
• Positive Sentiment: Progress on denifanstat: Wedbush Securities said Sagimet is making “good progress” toward bringing denifanstat to U.S. patients. Positive commentary on the company’s lead drug candidate could support sentiment because future valuation depends heavily on clinical and regulatory execution. Sagimet making progress on denifanstat
• Neutral Sentiment: Short-interest data appears unreliable: Reported short interest was zero shares, unchanged from the prior period, with a zero days-to-cover ratio. Because the figures include an undefined percentage change and may reflect incomplete reporting, they provide little meaningful insight into trading pressure.
• Negative Sentiment: Quarterly loss slightly exceeded expectations: Sagimet reported a second-quarter 2026 loss of $0.26 per share, compared with analysts’ expectation of a $0.25 loss. The modest earnings miss reinforces that the company remains loss-making while it advances its pipeline. Sagimet second-quarter 2026 results
• Negative Sentiment: Director reduced holdings: Director George Kemble sold 20,206 shares for approximately $201,050, reducing his direct ownership by 24.5%. While insider sales can be routine, the transaction may weigh on sentiment because it signals reduced personal exposure by a company director.

Sagimet Biosciences Company Profile

Sagimet Biosciences (NASDAQ: SGMT) is a clinical-stage biotechnology company focused on developing novel therapies for fibrotic diseases. The company’s lead program, CM-101, is a first-in-class fusion protein designed to neutralize the chemokine CCL24 and interrupt key drivers of tissue fibrosis. Preclinical data have demonstrated CM-101’s potential to block fibrotic signaling pathways in multiple organ systems, and the company has advanced the program into early-stage clinical evaluation for indications such as nonalcoholic steatohepatitis and systemic sclerosis.

In addition to CM-101, Sagimet maintains a pipeline of preclinical candidates targeting inflammation-driven fibrotic processes.